智通财经APP获悉，荣昌生物(09995)涨超3%，截至发稿，涨2.59%，报17.46港元，成交额1798.13万港元。
海通证券发布研报称，公司三季报表现优异，营收持续增长。3Q24公司实现营收4.67亿元，yoy+34.60%，年初至今累计实现收入12.09亿元，yoy+57.10%。收入的增长主要系核心产品RC18、RC48的持续放量，其中RC18SLE适应症于今年起执行新的医保价格，RA适应症于今年7月份获批上市，预计快速贡献增量。
该行续指，3Q24公司净亏损2.91亿元，单季度亏损为4Q22以来最低。公司亏损的持续收窄主要系规模效应及工艺改进带来毛利率提升的同时，公司积极对费用率进行管控。实现销售费用率49.89%，同比下降4.75pct；实现管理费用率18.62%，同比降低4.13pct；实现研发费用74.32%，同比下降17.17pct，单季度研发费用3.47亿元，环比2Q24有所下降。截至9月30日，公司拥有11.2亿元现金储备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.